Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 164

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 8
Chunk 164
---
9,861)Gain (loss)(2,753)(10,263)(24,398)Foreign currency translation(884)684 (854)Ending balance$116,561 $121,158 $129,012 The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below:December 28, 2024December 30, 2023December 31, 2022(in thousands)Beginning balance$122,653 $182,590 $51,712 Purchase of investments6,421 34,028 142,477 Distributions(6,432)(9,381)(2,732)Gain (loss) (1)(19,935)108,090 (2,377)Reduction for acquisition of entities (1)— (197,753)— Foreign currency translation(918)5,079 (6,490)Ending balance$101,789 $122,653 $182,590 (1) Refer to Note 2 – Acquisitions and Divestitures for further discussion of the 2023 Noveprim and SAMDI acquisitions.

80

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

9. FAIR VALUE

Assets and liabilities measured at fair value on a recurring basis are summarized below: December 28, 2024 Level 1Level 2Level 3TotalCurrent assets measured at fair value:(in thousands)Cash equivalents$— $30 $— $30 Other assets:Life insurance policies— 48,152 — 48,152 Total assets measured at fair value$— $48,182 $— $48,182 Accrued liabilities measured at fair value:Contingent consideration$— $— $25,000 $25,000 Other long-term liabilities measured at fair value:Contingent consideration— — 24,311 24,311 Total liabilities measured at fair value$— $— $49,311 $49,311  December 30, 2023 Level 1Level 2Level 3TotalCurrent assets measured at fair value:(in thousands)Cash equivalents$— $29 $— $29 Other assets:Life insurance policies— 40,912 — 40,